Adeno-associated viruses, illustration

Uncovering the Secrets of AAV for Improved Cell and Gene Therapies

We are all keenly aware that viruses can negatively impact our lives, but what about viruses that shape our existence and even improve some of its outcomes? In the past several decades, advances in cell and gene therapies have exploded due to innovations with adeno-associated virus (AAV). In this GEN webinar, sponsored by OXGENE, our notable presenter Dr. Ryan Cawood will discuss how TESSA technology enhances both AAV production yields and particle quality by suppressing adenoviral late gene expression.
Artificial Intelligence

The Generation & Commercialization of Innovation: Who is in the Room/Lab with Fiona Murray

In this Keynote webinar—the third in a “Women in Science” series co-hosted by GEN and the Rosalind Franklin Society—we will be joined by Fiona Murray, the Associate Dean of Innovation and Inclusion at the MIT School of Management and William Porter (1967) Professor of Entrepreneurship. Murray is the co-director of MIT’s Innovation Initiative and Faculty Director of the MIT Legatum Center for Entrepreneurship and Development.
DNA Sequencing Sanger Digital Background Binary Code

Therapeutic Advances Using In Vivo CRISPR Genome Editing

In this webinar hosted by GEN and The CRISPR Journal, Dr. Laura Sepp-Lorenzino Chief Scientific Officer at Intellia, will share the company's progress in both in vivo and ex vivo genome editing approaches.
The human Microbiome, genetic material of all the microbes that live on and inside the human body.

Mastering the Microbiome: Treating Disease with Bacteria

In this episode of GEN Live, we’re excited to host three outstanding leaders in the field from industry and academia to discuss the new frontier of microbiome research, recent progress, clinical potential and future challenges.
Innovations in medicine Abstract Molecular Structure

Expanding the Druggable Space to Accelerate Lead Identification

What if there was a way to avoid many of the early drug discovery pitfalls? In this GEN webinar, sponsored by Twist Bioscience, our distinguished speaker Dr. Benedict Cross, CTO of PhoreMost, will tell us about a newly developed screening approach called PROTEINi that “pre-discovers” the identity of new phenotypically tractable targets and their mechanisms for drug development.
Doctors meeting

The Important Business of Clinical Trials: The Scientific, Regulatory, and Patient Implications

In this GEN Keynote webinar, part of The Women in Science series, Dr. Amy Abernethy will talk about her her work to develop systems by which health data can support patient care, drug development, personalized medicine, and scientific discovery. She will also provide a view into Verily's expansion into a full-scale clinical evidence generation platform.

Spatial Biology Redefines the Multiomics Approach

In this GEN Keynote webinar, genomics veteran Dr. Joe Beechem, CSO and SVP of Research and Development at NanoString, will put the excitement over spatial biology into context, as a scientist who had a front-row seat during the next-gen sequencing revolution. Dr. Kulasinghe will discuss the latest spatial transcriptomics research to understand the underlying tissue pathobiology associated with lung cancer and COVID-19.
Cancer cell and T cell

T-Cell Priming Targets Identified with Help from Single-Cell Genomics

In this GEN webinar, sponsored by 10x Genomics, we will hear about a newly developed experimental framework to probe for priming sites in systemic immune compartments for determinants of helper T cell-induced immunopathology.
Messenger RNA or mRNA strand 3D rendering illustration with copy space. Genetics, science, medical research, genome replication concepts.

The Future of RNA Therapeutics is Modular

In this webinar from GEN, The CRISPR Journal, and sponsored by TriLink, Professor Dan Peer will discuss the state of RNA-based therapeutics, particularly developing a self-assembled modular platform that enables the construction of a theoretically unlimited repertoire of RNA-targeted carriers.
T cell binding antigen, illustration

For Cell and Gene Therapy Products, Early Characterization is Critical

In some of the newest cell and gene therapies, the drug itself is subvisible in nature. So, how do you tell a good particle (like a cell) that should go into a patient from a harmful particle that should not? In this GEN webinar, sponsored Halo Labs, we are going to hear about a new way to determine the good and the bad from our distinguished presenter Dr. Bernardo Cordovez.
Scroll Up